GERMANMED®

JUNCTUREX®

- Treatment of degenerative and post-traumatic articular affections
- Substitution of synovial fluid
- Joint protection
- Improvement of joint function
- Reduction of joint pain
- Promotion of endogenous hyaluronic acid biosynthesis

Medical device III CE$_{0426}$

GERMANMED®

MADE IN ITALY

ARTICULAR AFFECTION

DESCRIPTION

JUNCTUREX 2% (40 mg) is a synovial fluid substitute based on Hyaluronic Acid (HA) which, thanks to its viscoelastic and lubricant properties, promotes the restoration of rheological conditions of the joints, altered in degenerative or post-traumatic conditions.

JUNCTUREX 2%

- *It releases the synovial fluid and improves the visco-elasticity*
- *It guarantees a relief of the painful symptomatology*
- *It praises anti-inflammatory and analgesic properties*
- *It enhances the endogenous hyaluronic acid synthesis*

DOSAGE

It is recommended an initial **3-weeks** cycle (one injection per week) followed by maintenance session/s.

THERAPEUTIC INDICATIONS

- Degenerative articular affection
  - *Knee osteoarthritis*
  - *Gonarthrosis*
- Post-traumatic articular affection
  - *Sports injuries*
  - *Accidental falls and trauma*

PRESENTATION

JUNCTUREX 2% is supplied in one package containing:

- 1 pre-filled syringe

Every syringe contains 2 ml of non-pyrogenic gel.

INGREDIENTS

Sodium hyaluronate (20 mg/ml), sodium chloride, sodium dihydrogen phosphate dihydrate, dibasic sodium phosphate dodecahydrate, WFI grade water.

REGULATORY STATUS

- Class III
- Free sale certificate
- CE certificate
- Certificate of origin
- ISO 13485 certificate
- US FDA registration

PLUS

No animal origin of hyaluronic acid
BIOTECHNOLOGICAL SYNTHESIS

PREFILLED SYRINGES

- *Pre-measured doses*
- *High level of accuracy*
- *Reduced dosing and medication errors*
- *Reduced risk of microbial contamination*

LINEAR HYALURONIC ACID

Less pain during the injection

HYALURONIC ACID MOLECULAR WEIGHT RANGE 1000 – 1500KDA



Hyaluronic acid WM < 500 kDa
Lower affinity to the hyaluronic acid receptors. No stimulation of hyaluronic acid endogenous biosynthesis is observed.

JUNCTUREX 2%
Best affinity to the hyaluronic acid receptors and best stimulation of hyaluronic acid biosynthesis.



Hyaluronic acid WM > 4000 kDa
The steric hindrance of the molecules limits their access to hyaluronic acid receptors. No stimulation of endogenous biosynthesis of hyaluronic acid is observed.

2%

The concentration of HA molecules in **JUNCTUREX 2%** offers more protection to synovial fluid and allows increased viscoelastic propreties to the joint cartilage in times of increased stress.

CLINICAL TEST

- **RISK ANALYSIS - according to UNI CEI EN ISO 14971**
- **CYTOTOXICITY for DIRECT CONTACT - according to UNI EN ISO 10993-1:2004**
- **MAXIMIZATION OF DELAYED HYPERSENSITIVITY (Allergic sensitization) - according to UNI EN ISO 10993-1:2004**
- **INTRACUTANEOUS REACTIVITY - according to UNI EN ISO 10993-1:2004**
- **SALMONELLA TYPHIMURIUM REVERSION TEST (Ames test) - according to UNI EN ISO 10993-1:2004**
- **CLINICAL EVALUATION – according to MEDDEV 2.7.1**
- **STABILITY - according to ICH Guidelines**

Medical device III CE 0426

GERMANMED®

MADE IN ITALY